Dr. James is a physician-scientist and bone tissue pathologist, with research interest in mesenchymal progenitor cells and bone tissue engineering. His clinical and research training was performed at University of California, San Francisco (UCSF), Stanford University, and University of California, Los Angeles (UCLA). For the last two years, he has led a research team at Johns Hopkins University (JHU) seeking to understanding the cellular and molecular bases of bone tissue regeneration in an effort to heal bones faster and better. His work has been published in 141 peer-reviewed publications and has been cited over 3,900 times.

For more, read about Dr. James's recent work in Tissue Engineering Part A:

NZhang L, Chang L, Xu J, Meyers CA, Yan N, Zou E, Ding C, Ting K, Soo C, Pang S, and James AW Frontal Bone Healing Is Sensitive to Wnt Signaling Inhibition via Lentiviral-Encoded Beta-Catenin Short Hairpin RNA. Tissue Engineering Part A. 2018 August 20.

Dr. Dahlgren started working in the field of tendon and ligament biology during her Large Animal Surgery Residency at Iowa State University more than 20 years ago. Her lab at the Virginia-Maryland College of Veterinary Medicine, established in 2004, focuses on comparative aspects of tendon biology in people and horses, including the biology of tendon healing and the role of mesenchymal stem cells (MSC) as trophic mediators. Dr. Dahlgren has a long-standing collaboration with Dr. Aaron Goldstein (Chemical Engineering, Virginia Tech) using bioactive scaffolds to provide topographical, mechanical, and biochemical cues to guide cell differentiation and extracellular matrix deposition for ligament tissue engineering. Dr. Dahlgren's recent publication using the transcription factor Scleraxis in combination with cyclic mechanical strain to drive MSC differentiation toward a ligament morphology is largely the work of Dr. Anne Nichols in partial fulfillment of her PhD in Biomedical and Veterinary Sciences.

For more, read about Dr. Dahlgren's work in Tissue Engineering Part A:

CNichols AEC, Were SR, Dahlgren LA Transient Scleraxis Overexpression Combined with Cyclic Strain Enhances Ligament Cell Differentiation. Tissue Engineering Part A. 2018 May 10.

Lars Lidgren received his MD in 1971, PhD in 1973, and became Chair of the Department of Orthopedics at Lund University in 1990. He has been one of the pioneers in systemic antibiotic prophylaxis in joint replacement and is the inventor of several new methods treating chronic osteomyelitis, bacterial arthritis, and knee prosthetic infection. Forty years ago, he started hands-on joint replacement courses. He has published extensively on national implant registers and biomaterials. In addition, a recent focus of his research has been cell-recruiting peptides and antibiotic-containing synthetic bone. Dr. Lidgren has authored and co-authored more than 400 publications in the fields of orthopaedics, biomaterials, infectious diseases, and tissue engineering. Dr. Lidgren is an honorary member of several major societies, including AAOS, RCS, EFORT and ICOR. In 1998, he initiated the worldwide Bone and Joint Decade 2000-2010. He is founder of the biotech companies Bone Support and Scandimed.

For more, read about Dr. Wood's recent work in Tissue Engineering Part A:

Sirka A, Raina DB, Isaksson H, Tanner KE, Smailys A, Kumar A, Tarasevicius S, Tägil M, Lidgren L. Calcium Sulphate/Hydroxyapatite Carrier for Bone Formation in the Femoral Neck of Osteoporotic Rats. Tissue Engineering Part A. 2018 June 1.

As a surgeon and scientist, Dr. Besner holds the H. William Clatworthy, Jr. Chair in Surgery and is the Chief of Pediatric Surgery at Nationwide Children's Hospital. Her research focuses on identifying novel therapeutic strategies to protect the intestines from necrotizing enterocolitis as well as the production of tissue engineered intestine for the treatment of short bowel syndrome. Dr. Besner's research has received continuous funding from the National Institutes of Health for the past 23 years. Dr. Besner received her undergraduate degree from Cornell University and medical degree from the University of Cincinnati, completed her General Surgery Residency at the Brigham & Women's Hospital, Pediatric Surgery training at Buffalo Children's Hospital, and research training in the laboratory of Dr. Judah Folkman where she discovered a new growth factor known as heparin-binding EGF-like growth factor (HB-EGF). Dr. Besner has made important contributions in both the clinical and basic science arenas. She is the author of more than 190 articles and has delivered over 450 local, national, and international presentations.

For more, read about Dr. Besner's work in Tissue Engineering Part A:

Liu Y, Cromeens BP, Wang Y, Fisher K, Johnson J, Chakroff J, and Gail E. Besner Comparison of Different In Vivo Incubation Sites to Produce Tissue-Engineered Small Intestine. Tissue Engineering Part A. 2018 March 1.

Dr. Gordana Vunjak-Novakovic is University Professor, the highest academic rank reserved for only a few active professors, and the Mikati Foundation Professor of Biomedical Engineering and Medicine at Columbia University. She is a world expert in engineering of human tissues for regenerative medicine and modeling of disease. With over 38,000 citations and h=112, she is one of the most highly cited individuals of all times. With her students, Dr Vunjak-Novakovic founded four biotech companies that are all based in New York City. She is a frequent advisor to government and industry. Among her many distinctions, she is a member of the Academia Europaea, AAAS, American Institute of Medical and Biological Engineering, National Academy of Engineering, National Academy of Medicine, and National Academy of Inventors.

For more, read about Dr. Vunjak-Novakovic's work in Tissue Engineering Part A:

Bernhard JC, Hulphers E, Rieder B, Ferguson J, Rünzler D, Nau T, Redl H, and Gordana Vunjak-Novakovic Perfusion Enhances Hypertrophic Chondrocyte Matrix Deposition, But Not the Bone Formation. Tissue Engineering Part A. 2018 March 2.

Dr. Huang first began working with dental stem cells in early 2000. Per Dr. Huang, his team was the first to show that dental stem cells can be utilized to de novo regenerate dental pulp and dentin in an emptied root canal space in vivo using a small animal model (2009). He also led efforts to investigate the molecular biology of dental stem cells in the context of their applications for pulp regeneration, including their stemness and differentiation into odontoblast lineages. He has worked extensively to provide prospective to the field in terms of outlining the important progress in the field of pulp regeneration and prospectively discussing what remains to be investigated in order to launch stem cell-based pulp regeneration in humans. Furthermore, besides establishing a tooth fragment model using SCID mice to study pulp regeneration which has since been used by many researchers in the field, his group also established a large animal model using mini-swine to investigate pulp and dentin tissue regeneration.

For more, read about Dr. Huang's recent work in Tissue Engineering Part A:

Zhu X , Liu J, Yu Z , Chen C-A, Aksel H , Azim AA, and Huang G T.-J Miniature Swine Model for Stem Cell-Based De Novo Regeneration of Dental Pulp and Dentin-Like Tissue. Tissue Engineering Part A. 2018 Feb 1.

Dr. Bowles's lab is focused on engineering cell function to better control tissue development in engineered tissues. He utilizes recent advances in CRISPR epigenome regulation of gene expression to precisely control cell activity in engineered tissues and is specifically interested in applying these techniques for use in tissue engineering, gene therapy, and immunoengineering to modulate tissue development and intervertebral disc degeneration for the treatment of back pain. Focused on back pain, a leading cause of disability, his lab is focused on modulating the interactions between the biomechanics of the intervertebral disc, the inflammatory environment of the intervertebral disc and the peripheral nervous system to both develop a better understanding of back pain and to develop novel therapeutics.

For more, read about Dr. Bowles's recent work in Tissue Engineering Part A:

Farhang N, Brunger JM, Stover JD, Thakore PI, Lawrence B, Guilak F, Gersbach CA, Setton LA, Bowles RD. CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments. Tissue Engineering Part A. 2017 Feb 28.